Trademark: 79309395
Status Date
Tuesday, April 12, 2022
Registration Number
6696150
Registration Date
Tuesday, April 12, 2022
Filing Date
Monday, December 21, 2020
Published for Opposition
Tuesday, January 25, 2022
5 Pharmaceutical preparations and substances for the diagnosis and treatment, and the prevention of breast, brain, colorectal and gastro-intestinal cancer; pharmaceutical preparations and substances used for detecting body fluids; pharmaceutical preparations and substances used for detecting pancreatic fluids; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cancer; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of digestive system disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of bone diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hyperlipidemia diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of gastrointestinal diseases; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypoglycemia; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of sarcoma; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of immune system diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of hypertension; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of respiratory diseases and disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of skin disorders; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of multiple sclerosis; pharmaceutical preparations and substances for the diagnosis and treatment, or the prevention of cardiovascular diseases; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating central nervous system disorders; diagnostic biomarker reagents for medical purposes; veterinary diagnostic reagents; fluorescent diagnostic reagents for veterinary purposes; fluorescent diagnostic test reagents for veterinary purposes; diagnostic test reagents for medical purposes; fluorescent diagnostic test reagents for medical purposes; fluorescent diagnostic reagents for medical purposes; pharmaceutical preparations and other preparations for destroying vermin, fungicides, herbicides; fluorescent tracer agent for medical diagnostics or veterinary purposes; chemical reagents for veterinary purposes; fluorescent chemical reagents for veterinary purposes; chemical reagents for medical purposes; fluorescent chemical reagents for medical purposes; reagents for medical purposes; fluorescent reagents for medical purposes; medical diagnostic reagents and assays for testing of body fluids; medical diagnostic reagents and analysis samples for testing of body fluids; medical fluorescent diagnostic reagents and assays for testing of body fluids; medical fluorescent diagnostic reagents and analysis samples for testing of body fluids; medical clinical diagnostic reagents; fluorescent reagents for the clinical diagnosis; therapeutic drugs and agents, namely, agents for the treatment of malignant tumors
1 Reagents for research purposes; reagents for chemical analyses other than for medical or veterinary purposes; reagents for use in scientific apparatus for chemical or biological analysis; diagnostic reagents for scientific or research use; diagnostic reagents and preparations, except for medical or veterinary use; chemicals, namely, chemicals used in industry, sulfonates, chemicals for use in agriculture, except fungicides, herbicides, insecticides and parasiticides
44 Medical testing services using fluorescent reagents for diagnostic or treatment purposes; medical analysis services for the analysis, diagnosis, and treatment of patients using fluorescent reagents provided by medical laboratories; medical analysis for the diagnosis and treatment of persons; medical diagnostic services; medical evaluation of breast, brain, colorectal and gastro-intestinal cancer; medical diagnostic services using fluorescent reagents; medical evaluation services of breast, brain, colorectal and gastro-intestinal cancer using fluorescent reagents; diagnosis of diseases; diagnosis of diseases using fluorescent reagents; diagnosis of cancer; diagnosis of cancer using fluorescent reagents; medical testing services relating to the diagnosis and treatment of disease; medical testing services relating to the diagnosis and treatment of disease using fluorescent reagents; medical analysis services relating to the diagnosis and treatment of disease using fluorescent reagents provided by medical laboratories; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis for the diagnosis of cancer; cancer screening services; cancer screening services using fluorescent reagents; medical services for the analysis of samples taken from patients provided by medical laboratories; fluorescence imaging examination for the medical diagnosis or treatment; providing information in the field of cancer prevention, screening, diagnosis and treatment; providing medical information; providing medical information on diagnosis using fluorescent reagents; providing information on medical diagnosis using fluorescent reagents; medical analysis for the diagnosis of cancer using fluorescent reagents; rental of medical apparatus and installations; rental of medical diagnostic apparatus and installations; rental of medical diagnostic apparatus using fluorescent reagents and medical apparatus and installations using fluorescent reagents; rental of medical measuring apparatus
The mark consists of a five pointed star design formed by five blue diamonds.
In the statement, line 3, after Chuo-Ku, ", Sapporo-shi, Hokkaido" should be should be inserted, and in the statement, line 4, after Japan, "060-0008" should be inserted.
The color(s) blue is/are claimed as a feature of the mark.
May 2, 2023
Notice Of Updated Registration Confirmation Emailed
Mar 28, 2023
Case Assigned To Post Registration Paralegal
Mar 28, 2023
Correction Under Section 7 ¿ Processed
Mar 23, 2023
Case Assigned To Post Registration Paralegal
Sep 20, 2022
Final Decision Transaction Processed By Ib
Aug 29, 2022
Final Disposition Notice Sent To Ib
Aug 29, 2022
Final Disposition Processed
Jul 12, 2022
Final Disposition Notice Created, To Be Sent To Ib
Jul 7, 2022
Teas Section 7 Request Received
Apr 12, 2022
Registered-Principal Register
Jan 30, 2022
Notification Processed By Ib
Jan 25, 2022
Official Gazette Publication Confirmation E-Mailed
Jan 25, 2022
Published For Opposition
Jan 5, 2022
Notification Of Possible Opposition Sent To Ib
Jan 5, 2022
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 5, 2022
Notification Of Notice Of Publication E-Mailed
Dec 23, 2021
Approved For Pub - Principal Register
Dec 21, 2021
Applicant/Correspondence Changes (Non-Responsive) Entered
Dec 21, 2021
Teas Change Of Correspondence Received
Dec 21, 2021
Teas Change Of Domestic Representatives Address
Dec 21, 2021
Attorney/Dom.Rep.Revoked And/Or Appointed
Dec 21, 2021
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Dec 21, 2021
Teas Change Of Owner Address Received
Dec 21, 2021
Teas/Email Correspondence Entered
Dec 21, 2021
Correspondence Received In Law Office
Dec 21, 2021
Teas Response To Office Action Received
Aug 1, 2021
Refusal Processed By Ib
Jul 12, 2021
Non-Final Action Mailed - Refusal Sent To Ib
Jul 12, 2021
Refusal Processed By Mpu
Jul 3, 2021
New Representative At Ib Received
Jun 25, 2021
Non-Final Action (Ib Refusal) Prepared For Review
Jun 24, 2021
Non-Final Action Written
Jun 16, 2021
Assigned To Examiner
May 19, 2021
Correction From Ib Entered - No Review Required
May 16, 2021
Correction Transaction Received From Ib
Apr 27, 2021
Application Filing Receipt Mailed
Apr 23, 2021
New Application Office Supplied Data Entered
Apr 22, 2021
Sn Assigned For Sect 66a Appl From Ib
Trademark Alertz updated from USPTO on 2030-01-24
